# EDGAR Filing Document

**Accession Number:** 0001477449
**File Stem:** 0001104659-23-027372
**Filing Date:** 2023-3
**Character Count:** 21245
**Document Hash:** e92c233b51c209374b32579dfa0ae3a8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-027372.hdr.sgml**: 20230301

**ACCESSION NUMBER**: 0001104659-23-027372

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230301

**DATE AS OF CHANGE**: 20230301

**EFFECTIVENESS DATE**: 20230301

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Teladoc Health, Inc.
- **CENTRAL INDEX KEY:** 0001477449
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
- **IRS NUMBER:** 043705970
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270181
- **FILM NUMBER:** 23694409

**BUSINESS ADDRESS:**
- **STREET 1:** 2 MANHATTANVILLE ROAD
- **STREET 2:** SUITE 203
- **CITY:** PURCHASE
- **STATE:** NY
- **ZIP:** 10577
- **BUSINESS PHONE:** 2036352002

**MAIL ADDRESS:**
- **STREET 1:** 2 MANHATTANVILLE ROAD
- **STREET 2:** SUITE 203
- **CITY:** PURCHASE
- **STATE:** NY
- **ZIP:** 10577

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Teladoc, Inc.
- **DATE OF NAME CHANGE:** 20091123

**As filed with the Securities and Exchange Commission on March 1, 2023**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**TELADOC HEALTH, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **04-3705970** |
| **(State or other jurisdiction of incorporation or organization)** | **(I.R.S Employer Identification No.)** |
| **2 Manhattanville Road, Suite 203<br> Purchase, New York** | <br> **10577** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Teladoc Health, Inc. 2015 Employee Stock Purchase Plan**

**(Full title of the plan)**

**Adam Vandervoort<br> Chief Legal Officer<br> Teladoc Health, Inc.<br> 2 Manhattanville Road, Suite 203<br> Purchase, New York 10577<br> (Name and address of agent for service)**

**(203) 635-2002<br> (Telephone number, including area code, of agent for service)**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer x Accelerated filer ¨ <br> Non-accelerated filer ¨ Smaller reporting company ◻ <br> Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

**REGISTRATION OF ADDITIONAL SHARES**

**PURSUANT TO GENERAL INSTRUCTION E**

Pursuant to General Instruction E of Form S-8, Teladoc Health, Inc. (the "Registrant") is filing this Registration Statement with the Securities and Exchange Commission (the "SEC") to register 187,234 additional shares of Common Stock under the Registrant's 2015 Employee Stock Purchase Plan pursuant to the provisions of such plan providing for an automatic annual increase in the number of shares reserved for issuance under such plan. This Registration Statement hereby incorporates by reference the contents of the Registrant's previous registration statements on [Form S-8 filed with the Commission on July 9, 2015 (Registration No. 333-205568)](https://www.sec.gov/Archives/edgar/data/1477449/000110465915050353/a15-6702_13s8.htm), [July 14, 2017 (Registration No. 333-219275)](https://www.sec.gov/Archives/edgar/data/1477449/000110465917044914/a17-17934_1s8.htm) and [March 1, 2021 (Registration No. 333-253705)](https://www.sec.gov/Archives/edgar/data/1477449/000110465921029990/tm217987d1_s8.htm) to the extent not modified or superseded hereby. In accordance with the instructional note of Part I of Form S-8 as promulgated by the SEC, the information specified by Part I of Form S-8 has been omitted from this Registration Statement.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

We incorporate by reference herein the following documents filed by the Registrant with the SEC:

&nbsp;&nbsp;&nbsp;&nbsp;(a) [Teladoc's Annual Report on Form 10-K, filed with the SEC on March 1, 2023;](https://www.sec.gov/ix?doc=/Archives/edgar/data/1477449/000155837023002559/tdoc-20221231x10k.htm)

&nbsp;&nbsp;&nbsp;&nbsp;(b) all other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the
 "Exchange Act"), since the end of the fiscal year covered by the Registrant's Annual Report referred to in (a) above
(other than the portions of these documents not deemed to be filed); and

&nbsp;&nbsp;&nbsp;&nbsp;(c) [the description of Teladoc's Common Stock contained in the prospectus included in Teladoc's registration statement on Form 8-A (File No. 001-37477), filed with the SEC on June 26, 2015, pursuant to the Exchange Act, and any amendment or report filed for the purpose of updating such description.](https://www.sec.gov/Archives/edgar/data/1477449/000110465915048025/a15-6702_98a12b.htm)

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated herein by reference from the date of filing of such documents. In no event, however, shall any information that the Registrant discloses under Item 2.02 or Item 7.01 of any Current Report on Form 8-K (or otherwise indicates that the information is being "furnished" on such Current Report on Form 8-K (and not "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section)) and any corresponding exhibits thereto, which the Registrant may furnish to the SEC from time to time, be incorporated by reference into, or otherwise become a part of, this Registration Statement. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is incorporated or is deemed to be incorporated by reference herein modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.

**Item 5. Interests of Named Experts and Counsel.**

The validity of the shares of the Registrant's Common Stock registered on this Registration Statement has been passed upon by Adam C. Vandervoort, Chief Legal Officer of the Registrant. Mr. Vandervoort beneficially owns an aggregate of less than one percent of the outstanding shares of the Registrant's Common Stock and is eligible to participate in the Plan on the same basis as other similarly eligible employees.

**Item 8. Exhibits.**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| <br>**Exhibit<br> Number** | <br>**Exhibit Description** | **Form** | **File No.** | **Exhibit** | **Filing<br> Date** |
| [4.1](https://www.sec.gov/Archives/edgar/data/1477449/000110465922067619/tm2217304d1_ex3-1.htm) | [Seventh Amended and Restated Certificate of Incorporation of Teladoc Health, Inc.](https://www.sec.gov/Archives/edgar/data/1477449/000110465922067619/tm2217304d1_ex3-1.htm) | [8-K](https://www.sec.gov/Archives/edgar/data/1477449/000110465922067619/tm2217304d1_ex3-1.htm) | [001-37477](https://www.sec.gov/Archives/edgar/data/1477449/000110465922067619/tm2217304d1_ex3-1.htm) | [3.1](https://www.sec.gov/Archives/edgar/data/1477449/000110465922067619/tm2217304d1_ex3-1.htm) | [6/2/22](https://www.sec.gov/Archives/edgar/data/1477449/000110465922067619/tm2217304d1_ex3-1.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1477449/000110465922067619/tm2217304d1_ex3-2.htm) | [Sixth Amended and Restated Bylaws of Teladoc Health, Inc.](https://www.sec.gov/Archives/edgar/data/1477449/000110465922067619/tm2217304d1_ex3-2.htm) | [8-K](https://www.sec.gov/Archives/edgar/data/1477449/000110465922067619/tm2217304d1_ex3-2.htm) | [001-37477](https://www.sec.gov/Archives/edgar/data/1477449/000110465922067619/tm2217304d1_ex3-2.htm) | [3.2](https://www.sec.gov/Archives/edgar/data/1477449/000110465922067619/tm2217304d1_ex3-2.htm) | [6/2/22](https://www.sec.gov/Archives/edgar/data/1477449/000110465922067619/tm2217304d1_ex3-2.htm) |
| [4.3](http://www.sec.gov/Archives/edgar/data/1477449/000155837018008258/tdoc-20180930ex413841d5f.htm) | [Specimen stock certificate evidencing shares of common stock.](http://www.sec.gov/Archives/edgar/data/1477449/000155837018008258/tdoc-20180930ex413841d5f.htm) | [10-Q](http://www.sec.gov/Archives/edgar/data/1477449/000155837018008258/tdoc-20180930ex413841d5f.htm) | [001-37477](http://www.sec.gov/Archives/edgar/data/1477449/000155837018008258/tdoc-20180930ex413841d5f.htm) | [4.1](http://www.sec.gov/Archives/edgar/data/1477449/000155837018008258/tdoc-20180930ex413841d5f.htm) | [11/1/18](http://www.sec.gov/Archives/edgar/data/1477449/000155837018008258/tdoc-20180930ex413841d5f.htm) |
| [5.1](tm237713d1_ex5-1.htm) | [Opinion of Adam C. Vandervoort regarding legality of Teladoc Health, Inc. common stock being registered.](tm237713d1_ex5-1.htm) |  |  |  | [\*](tm237713d1_ex5-1.htm) |
| [23.1](tm237713d1_ex23-1.htm) | [Consent of Ernst & Young LLP, independent registered public accounting firm for Teladoc Health, Inc.](tm237713d1_ex23-1.htm) |  |  |  | [\*](tm237713d1_ex23-1.htm) |
| [23.2](tm237713d1_ex5-1.htm) | [Consent of Adam C. Vandervoort (contained in Exhibit 5.1).](tm237713d1_ex5-1.htm) |  |  |  | [\*](tm237713d1_ex5-1.htm) |
| [24.1](#a_001) | [Powers of Attorney (included on the signature page)](#a_001) |  |  |  | [\*](#a_001) |
| [99.1](https://www.sec.gov/Archives/edgar/data/1477449/000155837021009808/tdoc-20210630xex10d1.htm) | [Teladoc Health, Inc. 2015 Employee Stock Purchase Plan.](https://www.sec.gov/Archives/edgar/data/1477449/000155837021009808/tdoc-20210630xex10d1.htm) | [10-Q](https://www.sec.gov/Archives/edgar/data/1477449/000155837021009808/tdoc-20210630xex10d1.htm) | [001-37477](https://www.sec.gov/Archives/edgar/data/1477449/000155837021009808/tdoc-20210630xex10d1.htm) | [10.1](https://www.sec.gov/Archives/edgar/data/1477449/000155837021009808/tdoc-20210630xex10d1.htm) | [8/2/21](https://www.sec.gov/Archives/edgar/data/1477449/000155837021009808/tdoc-20210630xex10d1.htm) |
|  |  |  |  |  | \* |
| [107](tm237713d1_exfilingfees.htm) | [Filing Fee Table](tm237713d1_exfilingfees.htm) |  |  |  |  |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Purchase, State of New York, on March 1, 2023.

---

| | |
|:---|:---|
| **Teladoc Health, Inc.** | **Teladoc Health, Inc.** |
| By: | /s/ Jason Gorevic |
|  | Jason Gorevic |
|  | Chief Executive Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints Adam Vandervoort and Mala Murthy, and each of them acting individually, his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by Teladoc Health, Inc., and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; **Signature** | &nbsp;&nbsp; **Title** | &nbsp;&nbsp; **Date** |
| &nbsp;&nbsp;/s/ Jason Gorevic | &nbsp;&nbsp;Chief Executive Officer and Director | &nbsp;&nbsp;March 1, 2023 |
| &nbsp;&nbsp;Jason Gorevic | &nbsp;&nbsp;(Principal Executive Officer) |  |
| &nbsp;&nbsp;/s/ Mala Murthy | &nbsp;&nbsp;Chief Financial Officer | &nbsp;&nbsp;March 1, 2023 |
| &nbsp;&nbsp;Mala Murthy | &nbsp;&nbsp;(Principal Financial Officer) |  |
| &nbsp;&nbsp;/s/ Richard J. Napolitano | &nbsp;&nbsp;Chief Accounting Officer | &nbsp;&nbsp;March 1, 2023 |
| &nbsp;&nbsp;Richard J. Napolitano | &nbsp;&nbsp;(Principal Accounting Officer) |  |
| &nbsp;&nbsp;/s/ David B. Snow, Jr. | &nbsp;&nbsp;Chairman | &nbsp;&nbsp;March 1, 2023 |
| &nbsp;&nbsp;David B. Snow, Jr. |  |  |
| &nbsp;&nbsp;/s/ Karen L. Daniel | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 1, 2023 |
| &nbsp;&nbsp;Karen L. Daniel |  |  |
| &nbsp;&nbsp;/s/ Sandra L. Fenwick | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 1, 2023 |
| &nbsp;&nbsp;Sandra L. Fenwick |  |  |
| &nbsp;&nbsp;/s/ William H. Frist, M.D. | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 1, 2023 |
| &nbsp;&nbsp;William H. Frist, M.D. |  |  |
| &nbsp;&nbsp;/s/ Catherine Jacobson | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 1, 2023 |
| &nbsp;&nbsp;Catherine Jacobson |  |  |
| &nbsp;&nbsp;/s/ Thomas G. McKinley | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 1, 2023 |
| &nbsp;&nbsp;Thomas G. McKinley |  |  |
| &nbsp;&nbsp;/s/ Kenneth H. Paulus | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 1, 2023 |
| &nbsp;&nbsp;Kenneth H. Paulus |  |  |
| &nbsp;&nbsp;/s/ David L. Shedlarz | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 1, 2023 |
| &nbsp;&nbsp;David L. Shedlarz |  |  |
| &nbsp;&nbsp;/s/ Mark D. Smith | &nbsp;&nbsp;Director | &nbsp;&nbsp;March 1, 2023 |
| &nbsp;&nbsp;Mark D. Smith, M.D. |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](tm237713d1_ex5-1img001.jpg)

March 1, 2023

Teladoc Health, Inc.

2 Manhattanville Road, Suite 203

Purchase, NY 10577

Ladies and Gentlemen:

I have acted as counsel to Teladoc Health, Inc., a Delaware corporation (the "Company"), in connection with the Registration Statement on Form S-8 (the "Registration Statement") of the Company, filed with the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended (the "Act"), and the rules and regulations thereunder (the "Rules"). The Registration Statement relates to the registration under the Act of up to 187,234 shares of common stock, par value $0.001 per share, of the Company (the "Shares") issuable pursuant to the Teladoc Health, Inc. 2015 Employee Stock Purchase Plan (the "Plan").

In connection with the furnishing of this opinion, I have examined originals, or copies certified or otherwise identified to my satisfaction, of the Registration Statement and the Plan. In addition, I have examined (i) such corporate records of the Company that I have considered appropriate, including a copy of the certificate of incorporation, as amended and restated, and the bylaws, as amended and restated, of the Company, and copies of resolutions of the board of directors of the Company relating to the issuance of the Shares, and (ii) such other certificates, agreements and documents that I deemed relevant and necessary as a basis for the opinion expressed below. I have also relied upon certificates of public officials and the officers of the Company.

In my examination of the documents referred to above, I have assumed, without independent investigation, the genuineness of all signatures, the legal capacity of all individuals who have executed any of the documents reviewed by me, the authenticity of all documents submitted to me as originals, the conformity to the originals of all documents submitted to me as certified, photostatic, reproduced or conformed copies of valid existing agreements or other documents, the authenticity of all the latter documents and that the statements regarding matters of fact in the certificates, records, agreements, instruments and documents that I have examined are accurate and complete.

Based upon the above, and subject to the stated assumptions, exceptions and qualifications, I am of the opinion that the Shares have been duly authorized by all necessary corporate action on the part of the Company and, when issued, delivered and paid for in accordance with the terms of the Plan, the Shares will be validly issued, fully paid and non-assessable.

The opinion expressed above is limited to the General Corporation Law of the State of Delaware. My opinion is rendered only with respect to the laws, and the rules, regulations and orders under those laws, that are currently in effect. I hereby consent to use of this opinion as an exhibit to the Registration Statement. In giving this consent, I do not thereby admit that I come within the category of persons whose consent is required by the Act or the Rules.

---

| |
|:---|
| Very truly yours, |
| /s/ Adam C. Vandervoort |
| Adam C. Vandervoort |
| Chief Legal Officer |

---

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Teladoc Health, Inc. 2015 Employee Stock Purchase Plan of our reports dated March 1, 2023, with respect to the consolidated financial statements of Teladoc Health, Inc. and the effectiveness of internal control over financial reporting of Teladoc Health Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

New York, New York

March 1, 2023

## Ex-Filing

**Exhibit 107**

**CALCULATION OF FILING FEE TABLE**

**Form S-8**

(Form Type)

**Teladoc Health, Inc.**

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security <br> Type** | **Security<br> Class Title** | **Fee <br> Calculation<br> Rule** | **Amount<br> Registered (1)** |  | **Proposed<br> Maximum<br> Offering <br> Price Per<br> Share (2)** | **Maximum<br> Aggregate<br> Offering<br> Price (2)** | **Fee Rate** | **Amount of<br> Registration<br> Fee** |
| Equity | Common Stock, par value $0.001 per share | 457(c) and 457(h) | 187234 | (3) | $22.62 | $4235233.08 | 0.00011020 | $466.72 |
| Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | $4235233.08 |  | $466.72 |
| Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  |  |
| Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due |  |  | $466.72 |

---

(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration
Statement on Form S-8 (the "Registration Statement") shall also cover any additional shares of common stock, par value
$0.001 per share ("Common Stock"), of Teladoc Health, Inc. (the "Registrant") that become issuable under
the Teladoc Health, Inc. 2015 Employee Stock Purchase Plan (the "2015 ESPP") by reason of any stock dividend, stock split,
recapitalization or other similar transaction.

(2) Estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee. The price per share of Common
Stock is based on 85% of the average of the high and low prices reported for a share of Common Stock on the New York Stock Exchange on
February 27, 2023. Pursuant to the 2015 ESPP, the purchase price of the shares of Common Stock
reserved for issuance thereunder will be at least 85% of the lower of the fair market value of Common Stock on the Enrollment Date or
the Purchase Date (as such terms are defined in the 2015 ESPP).

(3) Represents the additional shares of Common Stock available for issuance under the 2015 ESPP resulting from automatic annual increases
on January 1, 2022 and 2023.